Ozempic

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
03-05-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
03-05-2023

Aktiivinen ainesosa:

semaglutide

Saatavilla:

Novo Nordisk A/S

ATC-koodi:

A10BJ06

INN (Kansainvälinen yleisnimi):

semaglutide

Terapeuttinen ryhmä:

Drugs used in diabetes

Terapeuttinen alue:

Diabetes Mellitus

Käyttöaiheet:

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Tuoteyhteenveto:

Revision: 10

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2018-02-08

Pakkausseloste

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
OZEMPIC 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
semaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor, pharmacist or
nurse.
–
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
–
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ozempic is and what it is used for
2.
What you need to know before you use Ozempic
3.
How to use Ozempic
4.
Possible side effects
5.
How to store Ozempic
6.
Contents of the pack and other information
1.
WHAT OZEMPIC IS AND WHAT IT IS USED FOR
Ozempic contains the active substance semaglutide. It
_ _
helps your body reduce your blood sugar level
only when blood sugar is too high and can help prevent heart disease.
Ozempic is used to treat adults (aged 18 years and older) with type 2
diabetes when diet and exercise
is not enough:
•
on its own – when you cannot use metformin (another diabetes
medicine) or
•
with other medicines for diabetes – when they are not enough to
control your blood sugar levels.
These may be medicines you take by mouth or inject such as insulin.
It is important that you continue with your diet and exercise plan as
told by your doctor, pharmacist or
nurse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE OZEMPIC
_ _
DO NOT USE OZEMPIC
•
if you are allergic to semaglutide or any of the other ingredients of
this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before using this medicine.
This medicine is not the same as insulin and you should not use it if:
•
you have type 1 diabetes – a condition where your body does no
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ozempic 0.25 mg solution for injection in pre-filled pen
Ozempic 0.5 mg solution for injection in pre-filled pen
Ozempic 1 mg solution for injection in pre-filled pen
Ozempic 2 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ozempic 0.25 mg
solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19
ml solution.
Ozempic 0.5 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37
ml solution.
Ozempic 1 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 4 mg semaglutide*
in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml
solution.
Ozempic 2 mg solution for injection
One ml of solution contains 2.68 mg of semaglutide*. One pre-filled
pen contains 8 mg semaglutide*
in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml
solution.
*Human glucagon-like peptide-1 (GLP-1) analogue produced in
_Saccharomyces cerevisiae _
cells
_ _
by
_ _
recombinant DNA technology
_._
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear and colourless or almost colourless, isotonic solution; pH=7.4.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ozempic is indicated for the treatment of adults with insufficiently
controlled type 2 diabetes mellitus
as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
3
For trial results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 03-05-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 21-02-2018
Pakkausseloste Pakkausseloste espanja 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 03-05-2023
Pakkausseloste Pakkausseloste tšekki 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 03-05-2023
Pakkausseloste Pakkausseloste tanska 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 03-05-2023
Pakkausseloste Pakkausseloste saksa 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 03-05-2023
Pakkausseloste Pakkausseloste viro 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto viro 03-05-2023
Pakkausseloste Pakkausseloste kreikka 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 03-05-2023
Pakkausseloste Pakkausseloste ranska 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 03-05-2023
Pakkausseloste Pakkausseloste italia 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto italia 03-05-2023
Pakkausseloste Pakkausseloste latvia 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 03-05-2023
Pakkausseloste Pakkausseloste liettua 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 03-05-2023
Pakkausseloste Pakkausseloste unkari 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 03-05-2023
Pakkausseloste Pakkausseloste malta 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto malta 03-05-2023
Pakkausseloste Pakkausseloste hollanti 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 03-05-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 21-02-2018
Pakkausseloste Pakkausseloste puola 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto puola 03-05-2023
Pakkausseloste Pakkausseloste portugali 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 03-05-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 21-02-2018
Pakkausseloste Pakkausseloste romania 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto romania 03-05-2023
Pakkausseloste Pakkausseloste slovakki 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 03-05-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 21-02-2018
Pakkausseloste Pakkausseloste sloveeni 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 03-05-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 21-02-2018
Pakkausseloste Pakkausseloste suomi 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 03-05-2023
Pakkausseloste Pakkausseloste ruotsi 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 03-05-2023
Pakkausseloste Pakkausseloste norja 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto norja 03-05-2023
Pakkausseloste Pakkausseloste islanti 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 03-05-2023
Pakkausseloste Pakkausseloste kroatia 03-05-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 03-05-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia